Sequence information
DRAVP ID DRAVPc038
Name Ansuvimab
Sequence
Molecular Formula Not Available
Condition/Disease Zaire ebolavirus infection
Group Approved, Investigational
Type Antibody
Description Ansuvimab, formerly mAb114, is a fully human IgG1 mAb derived from a survivor of the 1995 Kikwit EBOV outbreak 11 years after infection, which displays strong glycan-independent binding to a conserved region of the GP1,2 protein that is responsible for interacting with the host NPC1 protein to mediate EBOV endolysosomal escape, a key step in the EBOV lifecycle. Ansuvimab received FDA approval on December 21, 2020, and is currently marketed as Ebanga by Ridgeback Biotherapeutics, LP. Ansuvimab is just the second FDA-approved treatment for EVD.
Active sequence/Structure
External Links
DrugBank Accession Number DB16385
Pubchem ID 433770931
CHEMBL ID CHEMBL4594388
UNII TG8IQ19NG2
CAS 2375952-29-5
ClinicalTrails Information
NCT Number | Study Title | Condition/Disease | Status | Phase | Sponsor |
---|---|---|---|---|---|
NCT04822376 | Prophylaxis Vaccine Antibodies Ebola (PROVAE) | Ebolavirus Disease Prevention | Not yet recruiting | Phase 2 | ANRS, Emerging Infectious Diseases |